Schott Pharma Invests €100M in New Sterile Cartridge Facility in Hungary

Schott Pharma, a leading manufacturer of pharmaceutical packaging and delivery systems, has announced a significant expansion of its manufacturing capabilities in Hungary. The company is investing over €100 million ($115 million) to construct a new facility dedicated to the production of sterile ready-to-use (RTU) cartridges at its Lukácsháza site.

Expansion Details and Strategic Importance

The new facility, which has already broken ground, will focus on producing sterile RTU cartridges used for storing biologics, including GLP-1s, insulin, and hormone therapies for diabetes, obesity, and immunological diseases. This expansion comes less than a year after Schott Pharma inaugurated a glass syringe factory at the same location, underlining the company's rapid growth strategy in Europe.

Andreas Reisse, CEO of Schott Pharma, emphasized the strategic importance of this investment, stating, "This expansion reinforces our commitment to meeting the increasing demand for high-quality pharmaceutical packaging solutions."

Technological Advancements and Job Creation

Schott Pharma is equipping the new cartridge facility with cutting-edge manufacturing technology. The company reports that production will be "fully integrated and automated with minimal manual intervention," ensuring the highest standards of sterility for its cartridges.

The investment is expected to create more than 100 new jobs, significantly expanding the current workforce of 120 at the Lukácsháza site. This job creation aligns with Schott Pharma's ongoing efforts to strengthen its presence in the region and contribute to local economic growth.

Global Manufacturing Network

The Lukácsháza facility will become Schott Pharma's second site globally to produce sterile cartridges, complementing its existing plant in Switzerland. This expansion is part of a broader strategy to enhance the company's manufacturing footprint and meet growing global demand for pharmaceutical packaging solutions.

The investment in Hungary follows Schott Pharma's recent public listing on the Frankfurt Stock Exchange in September 2023, which CEO Andreas Reisse described as a "tremendous success." This move has positioned the company to pursue aggressive growth strategies and capitalize on emerging opportunities in the pharmaceutical packaging sector.